Over the past decades, pan-resistant strains of major bacterial pathogens have emerged rendering available antibiotics ineffective and putting at risk many achievements of modern medicine. New ways to identify clinically effective antimicrobials are urgently needed. However, the current antimicrobial development pipeline is inadequate because of high attrition and limited coverage of multi-drug resistant Gram-negative bacteria. Revitalizing antibiotic discovery requires a multidisciplinary approach starting at the bedside. Many factors affect the development of novel antibiotics such as our limited understanding of the physiology and heterogeneity of bacterial pathogens in patients and their interactions with microbiota. Bacteria growing in patients experience environments that are very different from standard laboratory conditions used for antibacterial discovery.
This conference will review the current knowledge on clinical activity of antibiotics; the role of microbiota; micro-tissue infection models; bacterial physiology in patients; mechanisms of antibacterial candidates, and non-conventional therapies. It will introduce students to emerging concepts that promise to accelerate antibacterial discovery, improve treatment regimens and uncover novel targets for eradicating pathogens.
It will bring together world-leading clinicians, microbiologists, tissue engineers and chemists who share common interests in the field and work towards the development of urgently needed control strategies to win the race against superbugs.